Journal of Immunology Research

Strategies to Boost Cancer Immunosurveillance


Publishing date
01 Mar 2021
Status
Closed
Submission deadline
16 Oct 2020

1Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

2Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran (INCMNSZ), Mexico City, Mexico

3University of Milan, Milan, Italy

This issue is now closed for submissions.
More articles will be published in the near future.

Strategies to Boost Cancer Immunosurveillance

This issue is now closed for submissions.
More articles will be published in the near future.

Description

In recent years, the role played by tumor-infiltrating immune cells, as a weapon to fight cancer, is gaining increasing attention and indeed, immune infiltrate characterization able to predict the outcome of immunotherapies represents a hot topic in cancer research. For instance, Immune Checkpoint Inhibitors (ICIs), targeting Cytotoxic T Lymphocyte Antigen 4 (CTLA4) or Programmed Cell Death 1 Ligand 1 (PD-L1)-Programmed Cell Death 1 (PD1) axis has impressively revolutionized the treatment landscape of many tumor types. Unfortunately, only a subset of patients benefit from these therapies aimed at unleashing anti-tumor immune response. In the majority of cancer patients, responsiveness to immunotherapy is negatively affected by the onset of immunosuppressive mechanisms, which impair T cell infiltration and cytotoxic activity and promote the accrual and activation of immunosuppressive cells, such as myeloid derived suppressor cells (MDSCs), regulatory T cells (Treg), Tumor-infiltrating macrophages (TAMs), in the tumor microenvironment (TME). There is an urgent need for clinical oncologists of new markers of tumor immune status to improve patients’ treatment allocation and to better understand trial results that are coming up.

Today’s efforts mainly focus on the dissection of the tumor microenvironment and on its genetics deregulation. Several features dictate the nature and function of immune infiltrate of TME favoring immune evasion, including oncogenic and metabolic pathways altered in tumor cells, the release of immune-related factors, miRNA, and microvesicles inducing reprogramming of immune cells towards immunosuppressive phenotype. Furthermore, new factors are emerging that can influence the immuno-evasion mechanisms of cancer cells (e.g. microbiota and its impact on the immune activation). Current knowledge of the mechanisms underlying the escape from immunosurveillance has been to date exploited to interfere with and/or disrupt these mechanisms using different approaches, but there is still room of improvement. To this aim, a deeper characterization of the complex and bidirectional cross-talk between cancer cells, immune populations and TME components is thus required to define innovative approaches to boost cancer immunosurveillance, at last maximizing the therapeutic potential of cancer immunotherapy.

The aim of this Special Issue is to provide recent findings in understanding how to boost the immune system to increase the number of immunotherapy responsive patients and to develop new unconventional approaches. We invite authors to submit original research and review articles addressing these issues.

Potential topics include but are not limited to the following:

  • Discovery and characterization of new cellular and molecular mechanisms underlying resistance to immunotherapy
  • Advances in cancer patients immune profiling, at tumor site and/or at systemic level
  • Identification of tissue- and blood-based predictive biomarkers of immunotherapy response
  • Novel approaches for reverting immunosuppression in the tumor microenvironment and favoring the efficacy of immunotherapy
  • Novel immunotherapy combinations at both preclinical and clinical level

Articles

  • Special Issue
  • - Volume 2021
  • - Article ID 6668573
  • - Review Article

Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation

Mariana Segovia-Mendoza | Susana Romero-Garcia | ... | Heriberto Prado-Garcia
  • Special Issue
  • - Volume 2020
  • - Article ID 7363084
  • - Research Article

Circulating Monocytic Myeloid-Derived Suppressor Cells Are Elevated and Associated with Poor Prognosis in Acute Myeloid Leukemia

Huiping Wang | Qianshan Tao | ... | Zhimin Zhai
  • Special Issue
  • - Volume 2020
  • - Article ID 1731457
  • - Research Article

M2 Macrophages Mediate the Resistance of Gastric Adenocarcinoma Cells to 5-Fluorouracil through the Expression of Integrin β3, Focal Adhesion Kinase, and Cofilin

Daniel Ngabire | Irvine Niyonizigiye | ... | Gun-Do Kim
  • Special Issue
  • - Volume 2020
  • - Article ID 8758090
  • - Research Article

Major Histocompatibility Complex Genes as Therapeutic Opportunity for Immune Cold Molecular Cancer Subtypes

Paweł Karpiński | Łukasz Łaczmański | Maria M. Sąsiadek
  • Special Issue
  • - Volume 2020
  • - Article ID 9435030
  • - Review Article

CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer

Rodrigo Catalán | Mario Orozco-Morales | ... | Oscar Arrieta
  • Special Issue
  • - Volume 2020
  • - Article ID 9678168
  • - Research Article

Myeloid Cells in Circulation and Tumor Microenvironment of Colorectal Cancer Patients with Early and Advanced Disease Stages

Salman M. Toor | Sarah Khalaf | ... | Eyad Elkord
  • Special Issue
  • - Volume 2020
  • - Article ID 6272498
  • - Review Article

Tumor-Derived Exosomes in Immunosuppression and Immunotherapy

Wioletta Olejarz | Agnieszka Dominiak | ... | Tomasz Lorenc
Journal of Immunology Research
 Journal metrics
Acceptance rate45%
Submission to final decision61 days
Acceptance to publication37 days
CiteScore5.600
Journal Citation Indicator0.600
Impact Factor4.818
 Submit

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.